SCHEMBL16908233

SCHEMBL16908233

N=C(N)c1c(F)cnc2[nH]ccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NUDT1 P36639 3/20 0.42
▸ PRKCI P41743 3/20 0.39
▸ AXL P30530 2/20 0.39
▸ RPS6KA3 P51812 2/20 0.39
▸ MKNK1 Q9BUB5 1/20 0.38
▸ MKNK2 Q9HBH9 1/20 0.38
▸ TRPA1 O75762 4/20 0.38
▸ JAK2 O60674 4/20 0.38
▸ JAK3 P52333 3/20 0.38
▸ AURKA O14965 1/20 0.38
▸ DAPK3 O43293 1/20 0.38
▸ PRKD3 O94806 1/20 0.38
▸ MAP4K4 O95819 1/20 0.38
▸ PAK4 O96013 1/20 0.38
▸ NTRK1 P04629 1/20 0.38
▸ CSF1R P07333 1/20 0.38
▸ RET P07949 1/20 0.38
▸ IGF1R P08069 1/20 0.38
▸ MET P08581 1/20 0.38
▸ PIM1 P11309 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16897118 0.82 PRKCI (0.40) NUDT1PRKCIAXLJAK2JAK3
SCHEMBL17371702 0.79 NUDT1 (0.43) NUDT1PRKCIAXLRPS6KA3MKNK1
SCHEMBL31177935 0.79 NUDT1 (0.43) NUDT1PRKCIAXLRPS6KA3MKNK1
SCHEMBL31541413 0.77 JAK3 (0.43) NUDT1PRKCIAXLRPS6KA3MKNK2
SCHEMBL1953766 0.75 TTBK1 (0.43) NUDT1PRKCIAXLRPS6KA3TRPA1
SCHEMBL24348505 0.74 NUDT1 (0.47) NUDT1PRKCIAXLRPS6KA3MKNK1
SCHEMBL2128440 0.74 RPS6KA3 (0.49) NUDT1PRKCIAXLRPS6KA3MKNK1
SCHEMBL1467759 0.73 NUDT1 (0.50) NUDT1PRKCIAXLRPS6KA3MKNK1
SCHEMBL29660498 0.73 NUDT1 (0.50) NUDT1PRKCIAXLRPS6KA3MKNK1
SCHEMBL16548436 0.70 PRKCI (0.53) NUDT1PRKCIAXLRPS6KA3MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2900666-B1 AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C CANCER RESEARCH TECH LTD (GB) 2020-11-04 — — EP disclosed
US-9914730-B2 Azaquinazoline inhibitors of Atypical protein Kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-03-13 — — US disclosed
US-9914730-B2 Azaquinazoline inhibitors of Atypical protein Kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-03-13 — — US disclosed
US-9896446-B2 Azaquinazoline inhibitors of atypical protein kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-02-20 — — US disclosed
US-9896446-B2 Azaquinazoline inhibitors of atypical protein kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-02-20 — — US disclosed
US-20160102094-A1 Azaquinazoline Inhibitors of Atypical Protein Kinase C IGNYTA, INC. (US) 2016-04-14 — — US disclosed
US-20160102094-A1 Azaquinazoline Inhibitors of Atypical Protein Kinase C IGNYTA, INC. (US) 2016-04-14 — — US disclosed
WO-2014052699-A9 AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C IGNYTA, INC. (US) 2015-07-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160102094-A1 Azaquinazoline Inhibitors of Atypical Protein Kinase C PRKCQ, PRKCZ, PRKCE NUDT1 2864/4885PRKCI 7/4885AXL 3636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback